Bausch Health Companies Inc.: Can Solta’s 136% Surge in South Korea Make It a Global Aesthetics Powerhouse?

Bausch Health Companies Inc. showed positive momentum in its Q1 2025 financial results. The company, which excludes Bausch & Lomb from this discussion, reported notable year-over-year revenue growth of 6% on a reported basis and 7% on an organic basis, alongside a 14% increase in adjusted EBITDA, reflecting a consistent upward trend as they celebrate their eighth consecutive quarter of year-over-year growth. The refinancing of $7.9 billion to extend near- and medium-term debts is a significant highlight, providing financial flexibility by extending maturities, which optimizes Bausch Health’s capital structure. This refinancing should be considered a major achievement despite it leading to increased interest expenses, which has necessitated an update in their guidance for adjusted cash flow from operations.